Global Liquid Biopsy Market Forecast 2017-2027

LONDON, January 24, 2017 /PRNewswire/ --

Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, Application and End User

Liquid Biopsies - our new study reveals trends, R&D progress, and predicted revenues
Where is the liquid biopsy market heading? If you are involved in this sector you must read this brand new report. Visiongain's report shows you the potential revenues streams to 2027, assessing data, trends, opportunities and business prospects there.

Discover How to Stay Ahead
Our 205-page report provides 190 tables, charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing liquid biopsy market. See how to exploit the opportunities.

Forecasts to 2027 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2027, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you find revenue forecasts for 4 different segmentations of the market, including forecasts for 3 sample types, 3 biomarker types, 7 applications and 4 end users:

• Liquid biopsy Market Forecasts to 2027, By Sample Type
- Blood
- Urine
- Other

• Liquid biopsy Technologies Market Forecasts to 2027, By Biomarker Type
- CTC
- ctDNA
- Exosomes

To see a report overview please email Sara Peerun on [email protected]

• Liquid biopsy Technologies Market Forecasts to 2027, By Application
- Lung Cancer
- Gastrointestinal Cancer
- Breast Cancer
- Colorectal Cancer
- Leukaemia
- Prostate Cancer
- Other Cancers

• Liquid biopsy Technologies Market Forecasts to 2027, By End User
- Hospitals
- Academic Institutes
- Diagnostic Laboratories
- Cancer Research Centres

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts 5 leading regional markets and 19 leading national markets:
• North America
- US
- Canada
• Europe
- Germany
- France
- UK
- Italy
- Spain
- Russia
- Rest of Europe
• APAC
- Japan
- China
- India
- South Korea
- Singapore
- Australia & New Zealand
• Rest of APAC
- Latin America
- Brazil
- Argentina
- Rest of Latin America
• MEA
- GCC
- South Africa
- Rest of MEA

There will be growth in both established and in developing countries. Our analyses show that the developing markets, China and India in particular, will continue to achieve high revenue growth to 2027. Developments worldwide in medical device regulation, especially in the US and Japan will influence the market.

Leading companies and the potential for market growth
Overall world revenue for liquid biopsy will surpass $0.4bn in 2017, our work calculates. We predict strong revenue growth through to 2027.

Our work identifies which organisations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Liquid biopsy Technologies Market report helps you
In summary, our 204-page report provides you with the following knowledge:
• Revenue forecasts to 2027 for the world liquid biopsy market and 4 different segmentations, with 3 sample types, 3 biomarker types, 7 applications and 4 end-user types - discover the industry's prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2027 for the leading 5 regional and 19 national markets - North America (US, Canada), Latin America (Brazil, Argentina, Rest of Latin America), Europe (Germany, UK, France, Italy, Spain, Russia and Rest of Europe), APAC (Japan, China, India, South Korea, Singapore, Australia & New Zealand and Rest of APAC), MEA (GCC, South Africa and Rest of MEA)
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the <enter sector> market and leading companies. You find data, trends and predictions.

Get our report today Global Liquid Biopsy Market Forecast 2017-2027: Analysis of the Liquid Biopsy Market by Sample Type, Biomarker, Application and End User. Avoid missing out - get our report now.

To request a report overview of this report please emails Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1782/Global-Liquid-Biopsy-Market-Forecast-2017-2027

Companies Mentioned in This Report 

American Pathology Partners Inc

Bayer HealthCare AG (Germany)

Biocept

Cerba Healthcare

Clearbridge BioMedics (Singapore)

German Partec GmbH

G-TAC Co., Ltd. (Japan)

HistoGeneX N.V

Janseen Global Services LLC

LabCorp (U.S.)

M3, Inc. (U.S.).

MDxHealth SA

Menarini Group

Merck KGaA

Merck Serono (Switzerland)

Miraca Life Sciences

NovioGendix Holding B.V

Pathway Genomics Corporation

Prime Health Services, Inc.

Roche Holding AG

Silicon Biosystems S.p.A

South Genetics Inc

Swift Biosciences

Sysmex Inostics GmbH

Trovagene

Organisations Mentioned in This Report 

Centre for Medicare and Medicaid Services (CMS)

Dana-Farber Cancer Institute (U.S.)

European Databank on Medical Devices (EUDAMED)

Japanese Ministry of Health Labour and Welfare (MHLW)

Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

Ministry of Health (China)

National Health Laboratory of Myanmar

National Institute of Statistics and Economic Studies

UK National Health Service (NHS)

United Nations (UN)

University of California (U.S.)

University of Michigan Comprehensive Cancer

University of Michigan Comprehensive Cancer Center

University of Southern California (U.S.)

US Food and Drug Administration (FDA)

US Oncology Research

USC Norris Comprehensive Cancer Center

World Health Organization (WHO)    

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd